Varinos is a clinical testing company developing and providing new genomic testing services.
We provide clinical tests in the field of reproductive medicine and obstetrics and gynecology, such as the "Endometrial Microbiome Testing," which has been made possible by ourlatest genome technology to detect extremely small amounts of bacteria, and "preimplantation genetic testing," which examines the genes and chromosomes of an embryo before conception to check for abnormalities.
Research and development area
In addition to the fields of reproductive medicine and obstetrics and gynecology, , we are expanding the use and potential of genomic medicine to include cancer and neonatal genetic diseases. We are developing unprecedented new genomic tests for the era of genomic medicine, where diagnosis is based on the diversity of genomes.
Our goal is to standardize clinical testing services using next-generation sequencers (NGS) and to provide clinical sequencing tests to patients timely,
Genome is a word synthesized from genes and chromosomes; it is all the genetic information in DNA. Genome information is like a blueprint for building the body.Genome medicine is to diagnose and treat diseases efficiently and effectively based on the comprehensive genomic information.
*NGS：Next Generation Sequencer
Next-generation sequencer (NGS) is an instrument that can read thousands to millions of DNAsequences at high speed. It is possible to analyze the genome (genetic information) at an overwhelmingly low cost and in a short time.
Realize speedy development and implementation technologies by our specialists for Next-generation sequencing analysis
The " Endometrial Microbiome Testing," developed by our company, is the world's first practical application of microbiome technology in the infertility field using a next-generation sequencer as a clinical test.
Operation using in-house facilities
Varinos Laboratory is a registered clinical laboratory (No. 177, Koto-ku, Tokyo), and implements unique quality control (QC) at key points in the testing process to minimize human error and ensure thorough accuracy control.
Research and development by our genome analysis specialists
Our experienced specialists in next-generation sequencing develop new genomic tests. We are actively engaged in collaborative research with universities, research institutes, and IVF clinics throughout Japan.
We develop and provide new clinical tests mainly in the fields of reproductive medicine and obstetrics and gynecology.
Endometrial Microbiome Testing business that has continued since the company was founded.
This is an Endometrial microbiome testing business that uses specimens collected from the vagina and uterus to examine the types and percentages of bacteria in the uterus.Learn more about Endometrial Microbiome Testing
Lactoferrin is found in breast milk and is important for protecting the body of babies and mothers from the inside out. varinos offers lactoferrin supplements.
※We have obtained a patent for the invention of the use of lactoferrin for intrauterine flora.Learn more about Lactoferrin
Preimplantation embryo genome testing and analysis project
We offer the Preimplantation Genome Test (PGT-A), which allows us to evaluate the chromosomes of embryos after IVF or ICSI before implantation. This is a testing project that uses genome analysis to examine chromosomal abnormalities, which are believed to be the cause of miscarriages, before implantation.
CEO Sakuraba, who introduced the first new type of prenatal diagnosis (NIPT) in Japan and was involved in the market development of genetic testing (NIPT and PGS) in the field of obstetrics and gynecology.
Co-founder Nagai is a specialist in genetic statistical analysis and database construction.
After working together at Illumina, a company that develops and markets next-generation sequencers, the two of us founded Varinos in 2017.
Thoughts at the time of founding: "There are no genome testing companies in Japan" and "Tests that are commonplace overseas cannot be performed in Japan" will be solved with our own technology.
At that time, about 15 years had passed since the birth of next-generation sequencing, a genome analysis technology that was initially used only for research purposes, but in the United States, Europe, China and other parts of the world, it was being applied to medical treatment, mainly for cancer and genetic diseases.
On the other hand, although Japan's research results are second to none in the world, in terms of medical applications, no company has been able to provide genomic testing as a clinical test to the medical field.
At the same time, in the field of fertility treatment and reproductive medicine, genomic tests such as Preimplantation Gamete Chromosome Aneuploidy Test (PGT-A), for example, are commonly used overseas, but have not been implemented in Japan.
Witnessing this situation, I developed genomic testing in Japan. We started developing and providing genomic testing services in the field of obstetrics and gynecology with the hope of helping patients in the field of infertility treatment and doctors in obstetrics and reproductive medicine who want to perform genomic testing but are unable to do so.
The name of Varinos is derived from the phrase "Variant for Diagnose".
The name reflects co-founder Nagai's desire to "contribute to people's health by implementing genomics in society.
Our future goal: we will be there for each and every one of you, weaving the future of your family.
In addition, the services we are providing now are focused on fertility treatment and reproductive medicine. However, this is only the first step. There are various fields, such as neonatal diseases and cancer, where genome testing can contribute to the future of patients by demonstrating its power.
With genome testing as our pillar, we will continue to develop and provide testing services in a variety of fields.
Founder and CEO
Received a Ph.D. (Science) from Saitama University in the post-doctoral program,Major in Genetics
RIKEN Center for Genomic Sciences,Genome Related National Projects
St. Jude Children's Hospital, USA
Basic research on cancer-related genes
Senior Manager, Laboratory Technology Department, GeneTech Corporation
Development of detection method of chromosome aneuploidy using maternal blood nucleated erythrocytes
Introduction of NIPT in Japan
Exective Clinical Sales Specialist, Illumina, Inc.
NIPT and PGT-A related technical sales
Next generation sequencing for medical applications
Founder and CEO, Varinos Inc. (present post)
Director, COO and CSO
Graduated from Hokkaido University Faculty of Veterinary Medicine (Veterinarian)
Astellas Pharma Inc.
Responsible for clinical development in Japan and other Asian countries
Business Producer, Dream Incubator Inc.
Engaged in consulting services for large companies and policy making support for government agencies.
Participated in the launch of the new Medical Marketer (MM) business as a main member and established the service.
Executive Officer, Business Development, Preferred Networks, Inc.
Director, COO and CSO, Varinos Inc. (current position)
PwC Arata Limited Liability Audit Corporation (passed the Certified Public Accountant Examination)
Worked as an in-charge at a megabank to support internal control evaluation
Director and General Manager, Corporate Administration Division, GA technologies Inc.
Achieved Mothers IPO in the 5th year after establishment and was in charge of M&A and IR after listing
Director and CFO, Caster Inc.
Director and CFO, RECLO Inc.
Director, CFO, Varinos Inc. (current position)
- Outside Director Tatsuzo Ishigami
- Outside Director Yutaro Kasai
- Outside Director Hiroyuki Misawa
- Full-time Corporate Auditor Natsuya Matsunaga
- Auditor Masanori Ishikawa
Feb. 20, 2017.
Contract analtical of clinical laboratories and development of genomic tests
1-1-20 Aomi, Koto-ku, Tokyo DiverCity Tokyo Office Tower 12F
+81 3 5422 6501